Fox Run Management, L.L.C. Sarepta Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$93.7 - $141.53 $255,988 - $386,659	-2,732 Reduced 28.66%	6,801 $880,000
Q4 2023 Feb 13, 2024	BUY	$67.31 - $124.76 $641,666 - $1.19 Million	9,533 New	9,533 $919,000
Q2 2022 Aug 12, 2022	BUY	$62.69 - $88.44 $21,377 - $30,158	341 Added 4.68%	7,626 $572,000
Q1 2022 May 10, 2022	BUY	$63.15 - $90.42 $460,047 - $658,709	7,285 New	7,285 $569,000
Q2 2021 Aug 05, 2021	SELL	$69.38 - $86.75 $340,100 - $425,248	-4,902 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$72.25 - $168.95 $354,169 - $828,192	4,902 New	4,902 $365,000
Q2 2019 Jul 17, 2019	SELL	$112.21 - $151.95 $222,849 - $301,772	-1,986 Closed	0 $0
Q1 2019 Oct 17, 2019	BUY	$106.67 - $151.68 $211,846 - $301,236	1,986 New	1,986 $237,000
Q4 2018 Jan 15, 2019	SELL	$97.32 - $148.76 $303,346 - $463,684	-3,117 Closed	0 $0
Q3 2018 Oct 05, 2018	BUY	$115.31 - $161.51 $359,421 - $503,426	3,117 New	3,117 $503,000
Q4 2017 Jan 18, 2018	SELL	$47.64 - $56.75 $214,380 - $255,375	-4,500 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$35.73 - $47.15 $160,785 - $212,175	4,500	4,500 $204,000

534

85.3M

1.55M

1.35M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $6.68B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.